The present disclosure provides lipid nanoparticles having a sphere like structure, compositions comprising the lipid nanoparticles and methods for delivery of the agents. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present disclosure relates to compositions of RNA encapsulated in lipid nanoparticles and methods of producing the same. The compositions can be used for delivery of mRNA to a subject. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Vaccines; vaccines for human use; flu vaccines Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development; Providing information about pharmaceutical research and development Medical information; pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Vaccines; vaccines for human use; flu vaccines Scientific research in the nature of conducting clinical trials for pharmaceutical preparations; scientific research in the nature of conducting clinical trials for flu vaccines; providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development Medical information; pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; Biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; Biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; Lipid nanoparticles for scientific, laboratory or medical research use Vaccine adjuvants; Drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines Medical services; medical information; providing a website featuring medical information
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Vaccines; vaccines for human use; flu vaccines Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development Medical information; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Vaccines; vaccines for human use; flu vaccines Scientific research in the nature of conducting clinical trials in the field of pharmaceutical preparations; conducting clinical trials in the field of flu vaccines; scientific research in the nature of providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development; Providing information about pharmaceutical research and development Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; and medical information, none of the foregoing for optician services, providing information relating to glasses, providing information relating to sunglasses, providing information relating to contact lenses, advisory and consultancy services and information relating to fitting of contact lenses, or vision correction and eye treatment
The present disclosure relates to the field of modified viruses and viral proteins. More particularly, this disclosure relates to modified haemagglutinin proteins, influenza viruses expressing such proteins and methods of making same
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development; Providing information about pharmaceutical research and development Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; and medical information
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Vaccines; vaccines for human use; flu vaccines Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development Medical information; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Vaccines; vaccines for human use; flu vaccines Providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development Medical information; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics
26.
RNA ENCODING VIRUS-LIKE PARTICLES AND USES THEREOF
The present disclosure relates to a composition comprising one or more ribonucleic acids (RNAs) encoding virus-like particle (VLP) forming elements of an influenza virus. The present disclosure further provides uses of the composition.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing educational information and medical information about immunology, Primary Immunodeficiency and Immunoglobulin G, as well as educational materials distributed in connection therewith
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
The present disclosure provides a method for quantifying a target protein in a sample making use of differentially isotopically labeled variants of the target protein.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/60 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances involving radioactive labelled substances
G01N 27/623 - Ion mobility spectrometry combined with mass spectrometry
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C07B 59/00 - Introduction of isotopes of elements into organic compounds
41.
METHODS AND REAGENTS FOR TREATING OR PREVENTING EBV
The present disclosure relates to Epstein-Barr Virus (EBV) (human herpesvirus 4) antigens. Specifically, proteins and uses thereof, and self-amplifying mRNA (sa-mRNA) encoding an EBV antigen and uses thereof. The present disclosure relates to vaccines and therapeutic agents, and production and uses thereof.
The present specification relates to vaccines comprising an mRNA polynucleotide encoding a coronavirus antigen; and an amphipathic cell penetrating RALA peptide.
Novel ionizable lipid compounds of Formula I or Formula II are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C07C 211/08 - Monoamines containing alkyl groups having a different number of carbon atoms
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/46 - Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
C07D 223/04 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present disclosure relates to the field of methods for culturing virally-infected cells. More particularly, this disclosure relates to methods of culturing cells with an influenza A virus. The disclosure relates further to impact of certain culture factors such as trypsin concentration, pH levels, incubation time, and combinations thereof on the production of viral proteins, particularly haemagglutinin.
The present disclosure provides a self-amplifying RNA (sa-mRNA) comprising an open reading frame encoding a replicase or a non-structural protein 4 (nsP4) and an open reading frame encoding peptide or polypeptide, wherein the open reading frame encoding the peptide or polypeptide is co-expressed with the replicase or nsP4.
The present disclosure provides a RNA comprising a nucleotide sequence encoding a modified hemagglutinin (HA) protein from an influenza virus, wherein the modified HA protein comprises at least one amino acid substitution or deletion relative to a native HA protein within a HA cleavage site.
The present disclosure provides a RNA comprising a nucleotide sequence encoding a modified hemagglutinin (HA) protein from an influenza virus, wherein the modified HA protein comprises at least one amino acid substitution or deletion relative to a native HA protein within a HA cleavage site.
The present specification relates to vaccines comprising an mRNA polynucleotide encoding an antigen from an infectious microorganism; and an amphipathic cell penetrating RALA peptide.
The use of certain ionizable cationic lipid compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and may be used in the delivery of the therapeutic and in methods of treating certain conditions, or for inducing an immune response.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present disclosure relates to SARS-CoV-2 RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of a SARS-CoV-2 infection or COVID-19.
The present disclosure relates to a recombinant virus-like particle (VLP) comprising an antigen for use as a vaccine. In an aspect, the present disclosure relates to a recombinant VLP comprising a capsid fusion protein for use as a vaccine.
The present disclosure relates generally to methods of producing RNA from a DNA template. More particularly, the method of the present disclosure comprises an in vitro transcription method for producing RNA from close-ended DNA (ceDNA) templates.
The present disclosure relates to combination RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of diseases or conditions including respiratory syncytial virus (RSV).
The present disclosure relates to the field of influenza viruses. More particularly, this disclosure relates to donor or seed influenza viruses for use in preparing reassortant influenza viruses for vaccine production.
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07D 225/02 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The use of an ionizable cationic lipid in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, including conventional messenger RNA and self-amplifying messenger RNA, and may be used in the delivery of the therapeutic and in methods of treating certain conditions, or for inducing an immune response.
The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).
The present disclosure relates to lipid nanoparticles for delivery of RNA, the lipid nanoparticle comprising therein a nucleic acid-binding protein or peptide (e.g., a RNA-binding protein or peptide) bound to the RNA, and uses thereof.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in vaccine compositions. In some examples, the RNA or polynucleotide also encodes an adjuvant, such as cathelicidin or a fragment thereof. The present disclosure also relates to use of the RNAs, polynucleotides or compositions in methods of inducing an immune response in a subject.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present disclosure relates to compositions comprising multiple antigens of interest for use in vaccine formulations. The compositions comprise (a) a polynucleotide (such as an RNA) comprising a nucleotide sequence encoding an antigen and (b) an antigen polypeptide. The compositions can be used in inducing an immune response in a subject and/or in the treatment or prevention of a disease, such as a respiratory viral infection.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in vaccine compositions. In some examples, the RNA also encodes a chemoattractant, such as chemerin, C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10) or C-X-C motif chemokine ligand 11 (CXCL11). The present disclosure also relates to use of the RNAs and compositions in methods of inducing an immune response in a subject.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
The present disclosure relates to an RNA delivery vehicle comprising lipid nanoparticles comprising the RNA therein, and a RNA-binding protein or peptide coated on the exterior surface of the lipid nanoparticle, and uses thereof.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
Novel ionizable lipid compounds of Formula I-Het, Formula I and Formula II are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07D 211/36 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07C 211/32 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by at least three rings containing dibenzocycloheptane or dibenzocycloheptene ring systems or condensed derivatives thereof
C07C 219/06 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
C07D 211/36 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
C07C 219/06 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
C07C 211/32 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by at least three rings containing dibenzocycloheptane or dibenzocycloheptene ring systems or condensed derivatives thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates to methods for quantifying mRNA capping efficiency. The methods use detectable labels for quantifying the amount of unlabelled mRNA in a sample. The method is applicable to RNA molecules of any sequence and may be used to obtain information on the physical properties of an RNA sample. The present disclosure also relates to kits which can be used for quantifying mRNA capping efficiency.
The present disclosure provides lipid nanoparticles having a sphere like structure, compositions comprising the lipid nanoparticles and methods for delivery of the agents. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
The present disclosure relates compositions of RNA encapsulated in lipid nanoparticles and methods of producing the same The compositions can be used for delivery of mRNA to a subject. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.
The present disclosure relates to lipid nanoparticles for delivery of DNA, the lipid nanoparticle comprising therein a DNA-binding protein or peptide bound to the DNA, and uses thereof.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present disclosure relates to the field of modified viruses and viral proteins. More particularly, this disclosure relates to modified haemagglutinin proteins, influenza viruses expressing such proteins and methods of making same.
The present disclosure relates to a composition comprising one or more ribonucleic acids (RNAs) encoding virus-like particle (VLP) forming elements of an influenza virus. The present disclosure further provides uses of the composition.
The present disclosure relates to multicistronic RNA vaccines and uses thereof. The present disclosure also relates to multicistronic conventional mRNA vaccines and uses thereof. The present disclosure further relates to multicistronic self-replicating RNA vaccines and uses thereof
The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self-replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a subgenomic promoter, wherein the antigen is from SARS-CoV-2, and wherein the antigen is a Spike (S) protein or a nucleocapsid (N) protein.
The present disclosure provides a method for purifying linear DNA prior to its use to produce RNA, the method comprising ultrafiltering and diafiltering a solution comprising the linear DNA with a membrane having a molecular weight cut off of 200kDa or less. mRNA-based therapies have been shown to be effective in the treatment or prevention of conditions, e.g., in the form of mRNA-based vaccines for the prevention of COVID-19. DNA used in the production of mRNA-based therapies must be sufficiently pure to produce the therapies.
